Intrathecal application of PD-1 antibody in metastatic solid tumors with leptomeningeal disease
- Conditions
- leptomeningeal disease
- Registration Number
- 2024-514068-14-00
- Lead Sponsor
- Universitaetsklinikum Tuebingen AöR
- Brief Summary
To assess the maximum tolerable dose and safety of intrathecal (IT) PD-1 antibody administration
- Detailed Description
Leptmeningeal disease (LMD) is an aggressive subtype of metastatic disease in the central nervous system (CNS) and has a poor prognosis with a median overall survival of a few months.The IT-PD1 trial group wants to contribute to an improvement of this situation for LMD patients by using an intrathecal application route for the PD1 antibody, i.e. a drug that has shown clinical efficacy in the underlying tumor via the intravenous route.
Recruitment & Eligibility
- Status
- Ongoing, recruiting
- Sex
- Not specified
- Target Recruitment
- 49
Must be ≥ 18 years at the time of signing the informed consent
Neurological examination (NANO scale) (Nayak et al., 2017)
MRI: the assessment at baseline and for subsequent time points should be based on the LANO scorecard (see appendix) according to (Le Rhun et al., 2019)
Ability to undergo intrathecal therapy via an intraventricular catheter (e.g. Ommaya reservoir)
Primary tumor tissue for the assessment of PD-1 and PD-L1 is optional at the timepoint of inclusion and enrollment but does need to be shipped before end of the trial
Female Patient of childbearing potential1 and male patients with female partner of childbearing potential1 is willing to use highly effective contraceptive methods during treatment and for 150 days (male or female, see SmPC) after the last dose. Recommendations highly effective contraceptive methods are: a. combined hormonal contraception associated with inhibition of ovulation (oral-, intravaginal, -transdermal) b. progestogen-only hormonal contraception associated with inhibition of ovulation (pral injectable, implantable), c. intrauterine device (IUD), d. intrauterine hormone - releasing system (IUS), e. bilateral tubal occlusion, f. vasectomized partner2, g. sexual abstinence3 1 For the purpose of this document, a female is considered of childbearing potential (FCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. For the purpose of this document, a man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy. 2Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the WOCBP trial participant and that the vasectomized partner has received medical assessment of the surgical success 2 In the context of this guidance sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.
Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures
Patients with a “good risk” status as defined by the NCCN guidelines (version 1.2021)
Tumor board protocol confirming: - a clinical recommendation for intrathecal therapy and evaluation of trial enrollment - a statement on the potential necessity of additional systemic treatment of metastatic tumor outside the CNS
Able to adhere to the study visit schedule and other protocol requirements
All subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment
Patients with Karnofsky performance score > 50%
Diagnosis of LMD by CSF and/or MRI a. A thorough CSF evaluation must be performed in every patient prior to the inclusion in this trial. The reason is that a positive CSF cytology is considered the gold standard for LMD diagnosis. Furthermore, a thorough CSF evaluation Protocol EUDRACT 2021-001795-42 IT-PD1 Date/Version: 17.11.2023, V4 IT-PD1, protocol Page: 42 of 104 will allow the thorough assessment of potential differential diagnoses (for example viral meningitis, bacterial meningitis, aseptic meningitis, sarcoidosis etc.) b. Presence of malignant cells on CSF cytology. The frequency of CSF evaluation is based on guideline of the German Society of Neurology: Please note that the first lumbar puncture is only 50-60% sensitive. Repeat collection increases sensitivity up to approximately 80%. Thus, a negative first CSF evaluation should at least be repeated once. According to guidelines from the German Society for Neurology each CSF collection should draw enough, i.e. at least 5- 10 ml CSF and should be processed within one hour of collection. c. MRI diagnosis of LMD: pial enhancement, pial nodular manifestations (as defined per LANO criteria, see appendix). d. A positive CSF cytology and an MRI evidence is enough to determine the LMD diagnosis. e. Please note that approximately 20% of patients with symptomatic LMD might lack positive CSF cytology even upon repeated puncture. In these cases, the LMD diagnosis can also be performed based on cerebral/spinal MRI manifestations and by exclusion of differential diagnosis. f. In the absence of diagnostic findings for LMD in the CSF: patients must present with typical clinical and MRI signs of LMD (Le Rhun et al., 2017). If the CSF has signs of pleocytosis (BUT NOT any malignant, atypical or suspicious cells) the differential diagnosis for CSF pleocytosis (aseptic meningitis, viral meningitis, bacterial meningitis) must be excluded. g. Some centers perform biopsies of leptomeninges for obtaining a LMD diagnosis. The LMD diagnosis will be based on histology and should be documented accordingly. Yet, a histological diagnosis of LMD is NOT required for the inclusion in this trial.
If radiation therapy had occurred: Please make sure that a documentation of the past radiation therapy is available (including applied dosage and radiation therapy fields): a. Participants eligible for IT-PD1 should have completed their radiation therapy due to clinical indication > 2 weeks prior to enrollment into the trial. b. All LMD patients without an indication for radiation therapy (per investigator‘s choice) can be enrolled immediately
Women during pregnancy and lactation
Patients with any disease resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy.
Clinically significant active infection, for example: a. Presence of human immunodeficiency virus b. Active hepatitis B virus/hepatitis C virus. HIV infection or active Hepatitis B or C infectionor active infections requiring oral or intravenous antibiotics or that can cause a severe disease and pose a severe danger to lab personnel working on patients’ blood or tissue (e.g. rabies)
Inability to undergo MRI with contrast agent.
The underlying primary tumor has not a registered and authorized indication in the European Union for intravenous treatment with Nivolumab, Pembrolizumab or Atezolizumab. The solide tumor registered are, i.e. melanoma, non-small cell lung cancer (NSCLC), Malignant pleural mesothelioma (MPM),renal cell carcinoma (RCC), Classical Hodgkin lymphoma (cHL), squamous cell cancer of the head and neck (SCCHN), urrothelial carcinoma, muscle invasive urothelial carcinoma (MIUC), colorectal cancer (CRC) with Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H), esophageal squamous cell carcinoma (ESCC), Adjuvant treatment of esophageal cancer (EC) or gastro-oesophageal junction cancer (GEJC), Gastric gastro‑oesophageal junction (GEJ) or oesophageal adenocarcinoma, triplenegative breast carcinoma. In addition, leptomeningeal disease of solid tumors with a high tumor mutational burden is also eligible.
Abnormal laboratory values for the following values in haematology, coagulation parameters, liver and renal function: a. Haemoglobin < 8 g/dl b. White blood cell count < 2.0 x 109/L) c. Platelet count decrease < 50 x 109/L d. Bilirubin > 2.5 x upper limit of normal (ULN) according to the performing laboratory‘s reference range. Note that benign hereditary hyperbilirubinemia e.g. Gilbert‘s syndrome is permitted. e. Alanine aminotransferase > 3 x ULN f. Aspartate aminotransferase > 3 x ULN g. Serum creatinine increase > 1.5 x ULN
Patients who have received live or attenuated vaccine therapy used for prevention of infectious disease within 4 weeks of the first IT application of Nivolumab.
Patients requiring chronic systemic corticosteroid therapy (> 10 mg prednisone or equivalent per day) or any other immunosuppressive therapies (including anti-TNF-a therapies).
Previous intrathecal Nivolumab application.
Patient at “poor risk” (NCCN guidelines version 1.2021).
The following differential diagnoses to LMD are exclusion criteria: a. Aseptic meningitis b. Viral meningitis c. Bacterial meningitis
History of hypersensitivity to monoclonal antibodies.
Participation in other clinical AMG or MDR trials or observation period of competing trials or if there is otherwise a high risk of insurance law issues intervening between two studies and if the participation affects the primary endpoint of the IT-PD1 study. In case of uncertainty, competing insurances must be contacted prior to participation.
A clinical condition that in the opinion of the investigator would interfere with the evaluation or interpretation of patient safety or trial results or that would prohibit the understanding of informed consent and compliance with the requirements of the protocol.
Any treatment-related toxicities from prior systemic anti-tumor or immune therapy not having resolved to CTCAE version 5.0 grade 1, with the exception of alopecia.
Patient with confirmed hisory of current autoimmune disease.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Primary Outcome Measures
Name Time Method To assess the maximum tolerable dose and safety of intrathecal (IT) PD-1 antibody administration To assess the maximum tolerable dose and safety of intrathecal (IT) PD-1 antibody administration
- Secondary Outcome Measures
Name Time Method Overall survival Overall survival
Trial Locations
- Locations (8)
Klinikum Der Landeshauptstadt Stuttgart gKAöR
🇩🇪Stuttgart, Germany
Universitaetsklinikum Mannheim GmbH
🇩🇪Mannheim, Germany
Klinikum rechts der Isar der TU Muenchen AöR
🇩🇪Munich, Germany
Universitaetsklinikum Ulm AöR
🇩🇪Ulm, Germany
Universitaetsklinikum Tuebingen AöR
🇩🇪Tuebingen, Germany
Medical Center - University Of Freiburg
🇩🇪Freiburg Im Breisgau, Germany
SLK-Kliniken Heilbronn GmbH
🇩🇪Heilbronn, Germany
Universitaetsklinikum Bonn AöR
🇩🇪Bonn, Germany
Klinikum Der Landeshauptstadt Stuttgart gKAöR🇩🇪Stuttgart, GermanyGerhard IllerhausSite contact+4971127830400g.illerhaus@klinikum-stuttgart.de